A case report of gastrointestinal bleeding during dual antiplatelet therapy in a patient with coronary heart disease

Cardiovascular disease continues to be the leading cause of death in both developed and developing countries. Low-dose acetylsalicylic acid is used worldwide for primary and secondary prevention of cardiovascular events on a long-term basis to reduce mortality and lethality. At the same time, the incidence of gastrointestinal bleeding associated with acetylsalicylic acid intake is steadily increasing. The presented case report illustrates the development of gastrointestinal bleeding against the background of dual antiplatelet therapy in a patient with coronary heart disease with a history of ulcers. A 65-year-old patient with an aggravated coronary history was routinely hospitalized in the cardiology department. On admission to the hospital, taking into account the increasing complaints of crushing pain behind the sternum, acute coronary syndrome was excluded in the patient, esophagogastroduodenoscopy was performed, which revealed a subcardia callous ulcer. On the same day, there was a negative trend in clinical manifestations in the form of syncope, hypotension up to 70/50 mmHg, vomiting «coffee grounds». According to the data of repeated emergency esophagogastroduodenoscopy a superficial ulcerous defect in the subcardia area with bleeding vessel in the bottom was revealed and combined endoscopic hemostasis was performed. Further examination of the patient revealed Helicobacter pylori infection, which in combination with other risk factors influenced the occurrence of this complication. First-line anti-ulcer eradication therapy was prescribed. The patient subjectively evaluated his condition as satisfactory and was discharged with recommendations for outpatient treatment. The purpose of this case report is to emphasize the importance of timely detection and treatment of gastrointestinal diseases in high-risk patients. This may allow for timely prevention of bleeding in patients with high-risk coronary heart disease in the future, taking into account a personalized approach.

1. Ezhov M.V., Kukharchuk V.V., Sergienko I.V., Alieva A.S., Antsiferov M.B., Ansheles A.A., Arabidze G.G., Aronov D.M., Arutyunov G.P., Akhmedzhanov N.M., Balakhonova T.V., Barbarash O.L., Boytsov S.A., Bubnova M.G., Voevoda M.I., Galstyan G.R., Galyavich A.S., Gornyakova N.B., Gurevich V.S., Dedov I.I., Drapkina O.M., Duplyakov D.V., Eregin S.Ya., Ershova A.I., Irtyuga O.B., Karpov R.S., Karpov Yu.A., Kachkovsky M.A., Kobalava Zh.D., Koziolova N.A., Konovalov G.A., Konstantinov V.O., Kosmacheva E.D., Kotovskaya Yu.V., Martynov A.I., Meshkov A.N., Nebieridze D.V., Nedogoda S.V., Obrezan A.G., Oleinikov V.E., Pokrovsky S.N., Ragino Yu.I., Rotar O.P., Skibitsky V.V., Smolenskaya O.G., Sokolov A.A., Sumarokov A.B., Filippov E., Halimov Yu.Sh., Chazova I.E., Shaposhnik I.I., Shestakova M.V., Yakushin S.S., Shlyakhto E.V. Disorders of lipid metabolism. Clinical Guidelines 2023. Russian Journal of Cardiology. 2023;28(5):5471. (In Russ.). https://doi.org/10.15829/1560-4071-2023-5471

2. Osadchuk M A., Osadchuk A. M. Erosive and ulcerative lesions of the digestive tract: optimization of diagnosis and management tactics. Terapevticheskii Arkhiv (Ter.Arkh.). 2022;94(2):271–276. (In Russ.). https://doi.org/10.26442/00403660.2022.02.201376

3. Yeomans N.D., Lanas A.I., Talley N.J., Thomson A.B., Daneshjoo R., Eriksson B., Appelman-Eszczuk S., Långström G., Naesdal J., Serrano P., et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Alimentary Pharmacology & Therapeutics. 2005;22:795–801. https://doi.org/10.1111/j.1365-2036.2005.02649.x

4. Hawkey C, Avery A, Coupland CAC, Crooks C, Dumbleton J, Hobbs FDR, Kendrick D, Moore M, Morris C, Rubin G, Smith M, Stevenson D; HEAT Trialists. Helicobacter pylori eradication for primary prevention of peptic ulcer bleeding in older patients prescribed aspirin in primary care (HEAT): a randomised, double-blind, placebo-controlled trial. Lancet. 2022 Nov 5;400(10363):1597-1606. PMID: 36335970. https://doi.org/10.1016/S0140-6736(22)01843-8

5. Sehested TSG, Carlson N, Hansen PW, Gerds TA, Charlot MG, Torp-Pedersen C, Køber L, Gislason GH, Hlatky MA, Fosbøl EL. Reduced risk of gastrointestinal bleeding associated with proton pump inhibitor therapy in patients treated with dual antiplatelet therapy after myocardial infarction. European Heart Journal. 2019 Jun 21;40(24):1963-1970. https://doi.org/10.1093/eurheartj/ehz104

6. Khan MY, Siddiqui WJ, Alvarez C, Aggarwal S, Hasni SF, Ahmad A, Eisen H. Reduction in postpercutaneous coronary intervention angina in addition to gastrointestinal events in patients on combined proton pump inhibitors and dual antiplatelet therapy: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2018 Aug;30(8):847-853. https://doi.org/10.1097/meg.0000000000001125

7. Isaikina MA, Isaikin AI, Akhmedzhanova LT. Efficacy and safety of aceclofenac in musculoskeletal diseases. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2023;15(2):114-119. (In Russ.) https://doi.org/10.14412/2074-2711-2023-2-114-119

8. Abraham NS, Noseworthy PA, Inselman J, Herrin J, Yao X, Sangaralingham LR, Cornish G, Ngufor C, Shah ND. Risk of Gastrointestinal Bleeding Increases With Combinations of Antithrombotic Agents and Patient Age. Clin Gastroenterol Hepatol. 2020 Feb;18(2):337-346.e19. Epub 2019 May 18. PMID: 31108228; PMCID: PMC7386161. https://doi.org/10.1016/j.cgh.2019.05.017

9. Neena S Abraham, Alan N Barkun, Bryan G Sauer, James Douketis, Loren Laine, Peter A Noseworthy, Jennifer J Telford, Grigorios I Leontiadis, American College of Gastroenterology-Canadian Association of Gastroenterology Clinical Practice Guideline: Management of Anticoagulants and Antiplatelets During Acute Gastrointestinal Bleeding and the Periendoscopic Period. Journal of the Canadian Association of Gastroenterology. April 2022;5(2):100–101. https://doi.org/10.1093/jcag/gwac010

10. Venerito M, Schneider C, Costanzo R, Breja R, Rohl F-W, Malfertheiner P. Contribution of Helicobacter pylori infection to the risk of peptic ulcer bleeding in patients on nonsteroidal anti-inflammatory drugs, antiplatelet agents, anticoagulants, corticosteroids and selective serotonin reuptake inhibitors. Aliment Pharmacol Ther.2018;47:1464–1471. https://doi.org/10.1111/apt.14652

11. Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, Liou JM, Schulz C, Gasbarrini A, Hunt RH, Leja M, O'Morain C, Rugge M, Suerbaum S, Tilg H, Sugano K, El-Omar EM; European Helicobacter andMicrobiota Study group. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022 Aug 8:gutjnl-2022-327745. Epub ahead of print. PMID: 35944925. https://doi.org/10.1136/gutjnl-2022-327745

12. Pemmasani G, Ashwath A, Aronow WS, Yandrapalli S, Leighton J, John S. Six-month cardiovascular prognostic impact of type 1 And type 2 myocardial infarction in patients hospitalized for gastrointestinal bleeding. Eur J Intern Med. 2023 Oct;116:51-57. Epub 2023 Jul 26. PMID: 37500309. https://doi.org/10.1016/j.ejim.2023.07.015

13. Gulizia MM, Colivicchi F, Abrignani MG, et al.; ESC Scientific Document Group; Faculty for approval of the Consensus Document. Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease. Eur Heart J Suppl. 2018 May;20(Suppl F):F1-F74. Epub 2018 May 31. PMID: 29867293; PMCID: PMC5978022. https://doi.org/10.1093/eurheartj/suy019